[HTML][HTML] Understanding COVID-19-associated coagulopathy
EM Conway, N Mackman, RQ Warren… - Nature Reviews …, 2022 - nature.com
Abstract COVID-19-associated coagulopathy (CAC) is a life-threatening complication of
SARS-CoV-2 infection. However, the underlying cellular and molecular mechanisms driving …
SARS-CoV-2 infection. However, the underlying cellular and molecular mechanisms driving …
NETosis, complement, and coagulation: a triangular relationship
CM de Bont, WC Boelens, GJM Pruijn - Cellular & molecular …, 2019 - nature.com
NETosis is a regulated form of neutrophil cell death that contributes to the host defense
against pathogens and was linked to various diseases soon after its first description in 2004 …
against pathogens and was linked to various diseases soon after its first description in 2004 …
Complement in disease: a defence system turning offensive
D Ricklin, ES Reis, JD Lambris - Nature Reviews Nephrology, 2016 - nature.com
Although the complement system is primarily perceived as a host defence system, a more
versatile, yet potentially more harmful side of this innate immune pathway as an …
versatile, yet potentially more harmful side of this innate immune pathway as an …
Platelets are versatile cells: New discoveries in hemostasis, thrombosis, immune responses, tumor metastasis and beyond
Platelets are small anucleate blood cells generated from megakaryocytes in the bone
marrow and cleared in the reticuloendothelial system. At the site of vascular injury, platelet …
marrow and cleared in the reticuloendothelial system. At the site of vascular injury, platelet …
HUS and atypical HUS
TS Jokiranta - Blood, The Journal of the American Society of …, 2017 - ashpublications.org
Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy characterized by
intravascular hemolysis, thrombocytopenia, and acute kidney failure. HUS is usually …
intravascular hemolysis, thrombocytopenia, and acute kidney failure. HUS is usually …
[HTML][HTML] SARS-2 Coronavirus–Associated Hemostatic Lung Abnormality in COVID-19: Is It Pulmonary Thrombosis or Pulmonary Embolism?
J Thachil, A Srivastava - Seminars in thrombosis and …, 2020 - thieme-connect.com
The coronavirus disease 2019 (COVID-19) pandemic has claimed several thousand lives
since the first case was described in Wuhan, China, in December 2019. 1 This has mainly …
since the first case was described in Wuhan, China, in December 2019. 1 This has mainly …
Cytokine storm associated coagulation complications in COVID-19 patients: Pathogenesis and Management
ABSTRACT Introduction SARS-CoV-2, the causative agent of COVID-19, attacks the
immune system causing an exaggerated and uncontrolled release of pro-inflammatory …
immune system causing an exaggerated and uncontrolled release of pro-inflammatory …
Haemostasis and innate immunity–a complementary relationship: a review of the intricate relationship between coagulation and complement pathways
CB Keragala, DF Draxler, ZK McQuilten… - British journal of …, 2018 - Wiley Online Library
Coagulation and innate immunity are linked evolutionary processes that orchestrate the host
defence against invading pathogens and injury. The complement system is integral to innate …
defence against invading pathogens and injury. The complement system is integral to innate …
Complement in ANCA-associated vasculitis: mechanisms and implications for management
M Chen, DRW Jayne, MH Zhao - Nature Reviews Nephrology, 2017 - nature.com
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of
potentially life-threatening autoimmune diseases. The main histological feature in the …
potentially life-threatening autoimmune diseases. The main histological feature in the …
Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia
S Holm, H Kared, AE Michelsen, XY Kong… - European Heart …, 2021 - academic.oup.com
Aims We recently reported five cases of vaccine-induced immune thrombotic
thrombocytopenia (VITT) 7–10 days after receiving the first dose of the ChAdOx1 nCoV-19 …
thrombocytopenia (VITT) 7–10 days after receiving the first dose of the ChAdOx1 nCoV-19 …